

Wednesday, September 10, 2003

COMPANY PRESS RELEASE

Transgenomic Announces Launch of SURVEYOR™ Product Line

New Technology Broadens Consumable Product Offerings and Facilitates Entry into New Markets

OMAHA, Neb., Sept. 10 / -- Transgenomic Inc. ([Nasdaq: TBIO](#)) announced today that it has launched the SURVEYOR line of bioconsumable kits for use in genetic variation discovery and detection. This product line complements and extends the capabilities of the company's WAVE® System instrument platform, as well as offering platform-independent mutation/polymorphism scanning capability. The SURVEYOR product line opens significant new market opportunities and is the latest example of Transgenomic's commitment to providing innovative solutions for researchers' ongoing and varied needs in the area of genetic variation analysis.

The key component of SURVEYOR Mutation Detection Kits is an enzyme that cleaves DNA at points where any type of DNA sequence variation exists, a significant improvement compared to related enzymes in its class. The resulting DNA fragments can then be analyzed by the Transgenomic WAVE System, fluorescent capillary electrophoresis or standard gel electrophoresis. SURVEYOR Kits provide a simple and robust method of scanning relatively large DNA fragments for both known and novel sequence variations.

SURVEYOR technology has already begun to enhance the productivity of early adopters pursuing functional genomics studies in plants and various other model organisms. David Caldwell, project leader at the Scottish Crop Research Institute, commented, "A critical aspect of implementing our reverse genetics approach in barley is the choice of a mutation detection method which enables us to scan target gene sequences in an automated fashion with high sensitivity and specificity, as well as reasonable cost. SURVEYOR technology facilitates the detection of mutations in larger fragments than can typically be covered by DNA sequencing, and analysis of the cleavage products on the WAVE 3500 HS System permits us to pool samples from up to 24 individual plants, greatly reducing the cost and increasing the speed of sample screening."

Collin D'Silva, Transgenomic's CEO, added, "SURVEYOR Mutation Detection Kits represent the next set of significant products resulting from our core competency in enzymology. This product line addresses a variety of market opportunities, from large-scale resequencing studies at major genomics centers to the work underway in thousands of individual laboratories driven by specific biological questions. We believe an increasing number of scientists in a variety of disciplines are beginning to incorporate genetic variation analysis as a component of their studies." D'Silva concluded, "SURVEYOR products lower the barriers to entry by offering cost effective and accurate genetic variation scanning capability that is compatible with several detection methods, allowing researchers to begin using SURVEYOR Kits in combination with existing laboratory equipment."

Data obtained using this technology will be presented at The Institute for Genomic Research's 15th Annual Genome Sequencing and Analysis Conference in Savannah, Ga., Sept. 21-24, 2003. The advantages of complementing the use of SURVEYOR Kits with Transgenomic's Optimase® Polymerase, a high-fidelity polymerase for PCR amplification, will also be presented.

SURVEYOR technology is based on intellectual property licensed exclusively from The Fox Chase Cancer Center, Philadelphia, Pa.

About Transgenomic

Transgenomic provides versatile and innovative research tools and related consumable products to the life sciences industry for the synthesis, separation, analysis and purification of nucleic acids and a wide

variety of nucleic acid-based specialty chemicals. Transgenomic's biosystems segment offers its WAVE Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. These systems have broad applicability to genetic research and molecular diagnostics. To date there have been approximately one thousand systems installed in over 30 countries around the world.

Through its nucleic acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents, used in applications such as genetic diagnostics and therapeutics. Manufacturing operations include a cGMP facility for the synthesis of oligonucleotides.

For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's Web site at www.transgenomic.com.

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to the superiority of SURVEYOR enzyme over other enzymes, the significance of the SURVEYOR product and its ability to address varied market opportunities, the cost effectiveness and accuracy of SURVEYOR Kits, and the incorporation by scientists of genetic variation analysis into their studies. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For confirmation of release or further information, please contact:

Mitchell L. Murphy
Transgenomic Inc.
402-452-5418
mmurphy@transgenomic.com

Robert J. Pogulis, Ph.D.
Transgenomic Inc.
845-782-9617
rpogulis@transgenomic.com